GSK1349572 Drug Interaction With Tenofovir
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00726336|
Recruitment Status : Completed
First Posted : July 31, 2008
Last Update Posted : October 15, 2010
|Condition or disease||Intervention/treatment||Phase|
|Healthy Subjects||Drug: GSK1349572 and tenofovir||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||16 participants|
|Official Title:||A Phase I, Open Label, Single Sequence,Drug Interaction Study Evaluating Plasma GSK1349572 and Tenofovir Pharmacokinetics in Healthy Adult Subjects (ING111604)|
|Study Start Date :||August 2008|
|Primary Completion Date :||October 2008|
- Plasma GSK1349572 steady-state AUC(0-tau), Cmax and Ctau following administration of GSK1349572 50 mg q24h for 5 days and following co-administration with TDF 300 mg q24h for 5 days
- Plasma tenofovir steady-state AUC(0-24), Cmax and Ct following administration of TDF 300 mg q24h for 7 days alone and following co-administration with GSK1349572 50 mg q24h for 5 days.
- Safety and tolerability parameters, including adverse event, concurrent medication, clinical laboratory, ECG, and vital signs assessments.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00726336
|United States, New York|
|GSK Investigational Site|
|Buffalo, New York, United States, 14202|
|Study Director:||GSK Clinical Trials, MD||GlaxoSmithKline|